Breast cancer is the second most common type of cancer among women in the US and the second leading cause of cancer death. HER2+ breast cancers represent ~20% of all cancer types, are highly invasive, and can be treated by using targeted therapies against the HER2 receptor. However, these therapies are challenged by the development of drug resistance, often induced by the presence of mutations in the cell-membrane proteins and receptors and/or by alternative signaling pathways that cross-talk with- or transactivate HER2+ triggered signaling. This study was aimed at investigating the cell membrane proteome of SKBR3 cells, representative of HER2+ breast cancers, and the signaling landscape and cellular responses elicited by the cell membrane receptors when the cells are stimulated with either growth factors or therapeutic drugs. It was hypothesized that the identification of a broad range of cell membrane proteins with roles in cancer progression and signaling crosstalk will lead to a more comprehensive understanding of the biological processes that sustain the proliferation of cancer cells, and will guide the selection of more efficient drug targets. The project was conceptualized in three stages: (1) profiling the cell membrane proteins of SKBR3 cells, (2) determining the functional role of the detected cell membrane proteins in the context of cancer hallmarks and exploring their mutational profile, and (3) analyzing the cellular events that occur in response to treatment with a single therapeutic agent or a combination of drugs. Mass spectrometry technologies were used for performing proteomic and phosphoproteomic profiling of SKBR3 cells, detecting changes in the abundance of the detected proteins, and identifying the presence of mutations in the cell membrane proteins. Orthogonal enrichment methods were developed for profiling the low-abundance cell membrane proteins, for generating a rich landscape of cell membrane receptors with various functional roles and relevance to the cancer hallmarks, and for enabling the detection of potentially new drivers of aberrant proliferation. The analysis of serum-starved, stimulated (with growth factors), or inhibited (with kinase inhibitors) cells revealed alternative protein players and crosstalk activities that determine the fate of cells, and that may fuel the development of resistance to treatment with drugs. The proteome profiles that were generated in this project expand the opportunities for targeting cancer-relevant processes beyond proliferation, which is commonly attempted, broadening the landscape to also include apoptosis, invasion, and metastasis. Altogether, the findings that emerged from this work will lay the ground for future studies that aim at developing more complex and effective targeted cancer treatment approaches. / Doctor of Philosophy / Breast cancer is one of the most common cancers among women in the US and the second major contributor to cancer-related deaths. Several therapies that have been developed for the treatment of cancer target the HER2 receptor, which is overexpressed in ~20% of breast cancers and results in a highly invasive cancer phenotype. However, most patients receiving these therapies observe cancer reoccurrence within a year due to the development of resistance to the therapeutic drug. The current challenge stands in identifying novel protein targets, and in developing new therapies that can be used in combination with the existing approaches to eradicate cancer. Research has indicated that proteins located at the cell membrane play crucial roles in cancer progression and invasion due to their involvement in cell response to stimuli and in initiating signaling cascades within the cell. Knowledge about the cell membrane proteins of HER2+ breast cancer cells is limited due to the challenges associated with their isolation. Therefore, this project was aimed at profiling the cell membrane proteins of HER2+ breast cancer cells, and their intra-cellular signaling activity, to provide insights into the behavior of these cells and to support the identification of potentially novel drug targets. The three objectives of the work were to (1) isolate the cell membrane proteins through various approaches using cell culture conditions that would encourage or discourage cancer cell growth, (2) identify the cancer-relevant signaling pathways and processes represented by the detected cell membrane proteins, and (3) investigate the behavior of cancer cells when treated with drugs. To approach these objectives, a powerful analytical technology, called mass spectrometry, was utilized. Mass spectrometry can accurately and simultaneously detect the presence of the proteins in a biological sample. Our study identified cell membrane proteins that are involved in cancer progression through various signaling pathways, and how these proteins interact with each other to drive the behavior of cells. The study also provided insights into how cancer cells respond when they are treated with various drugs, uncovering to the scientific community a variety of proteins with potential therapeutic value. Lastly, this study sheds light on the complex biology of breast cancer and highlights the importance of continued research to develop more effective treatments.

No description available.

Rapid advances in high-throughput data acquisition technologies, such as microarraysand next-generation sequencing, have enabled the scientists to interrogate the expression levels of tens of thousands of genes simultaneously. However, challenges remain in developingeffective computational methods for analyzing data generated from such platforms. In thisdissertation, we address some of these challenges. We divide our work into two parts. Inthe first part, we present a suite of multivariate approaches for a reliable discovery of geneclusters, often interpreted as pathway components, from molecular profiling data with replicated measurements. We translate our goal into learning an optimal correlation structure from replicated complete and incomplete measurements. In the second part, we focus on thereconstruction of signal transduction mechanisms in the signaling pathway components. Wepropose gene set based approaches for inferring the structure of a signaling pathway.First, we present a constrained multivariate Gaussian model, referred to as the informed-case model, for estimating the correlation structure from replicated and complete molecular profiling data. Informed-case model generalizes previously known blind-case modelby accommodating prior knowledge of replication mechanisms. Second, we generalize theblind-case model by designing a two-component mixture model. Our idea is to strike anoptimal balance between a fully constrained correlation structure and an unconstrained one.Third, we develop an Expectation-Maximization algorithm to infer the underlying correlation structure from replicated molecular profiling data with missing (incomplete) measurements.We utilize our correlation estimators for clustering real-world replicated complete and incompletemolecular profiling data sets. The above three components constitute the first partof the dissertation. For the structural inference of signaling pathways, we hypothesize a directed signal pathway structure as an ensemble of overlapping and linear signal transduction events. We then propose two algorithms to reverse engineer the underlying signaling pathway structure using unordered gene sets corresponding to signal transduction events. Throughout we treat gene sets as variables and the associated gene orderings as random.The first algorithm has been developed under the Gibbs sampling framework and the secondalgorithm utilizes the framework of simulated annealing. Finally, we summarize our findingsand discuss possible future directions.

Le mélanome cutané est le plus agressif des cancers de la peau. Sa dangerosité provient de sa grande capacité à former des métastases. A l’heure actuelle, la prévention et la détection précoce de la lésion primitive restent les seuls moyens d’aboutir à une guérison. En effet, ce cancer est particulièrement reconnu pour sa résistance aux thérapies actuelles sous sa forme métastatique. Le mélanome se développe à partir des mélanocytes de la peau, qui après des évènements oncogéniques, prolifèrent de manière anarchique dans l’épiderme. Par la suite, certaines cellules de la tumeur acquièrent un phénotype invasif qui leur permet de franchir la jonction dermo-épidermique et envahissent le derme, pour y proliférer et le coloniser en profondeur. Une fois dans le derme, les cellules de mélanome peuvent disséminer à distance par voie lymphatique et sanguine pour former des métastases dans les organes cibles. La dégradation de la jonction dermo-épidermique conduisant à l’invasion du derme est la première étape qui mène à la formation de métastase. Dans l’équipe on s’intéresse à l’étude des mécanismes de l’invasion dermique. Grâce au travail fourni, nous avons pu identifier un nouvel acteur moléculaire intervenant dans l’invasion précoce du mélanome cutané : La Tétraspanine 8. Le but de ce travail de thèse a donc été de définir le rôle et le mode d’action de cette protéine. Nous avons réussi à établir l’implication de la Tétraspanine 8 dans la perte d’adhérence des cellules de mélanome aux protéines de la matrice extracellulaire, en association avec une inhibition de l’activation de l’intégrine β1 et avec une diminution de la phosphorylation de la kinase ERK. Nous avons également obtenu des résultats impliquant la Tspan8 dans l’invasion du derme par les cellules de mélanome, en association avec augmentation de la stabilité de β-caténine. Enfin, les tests de tumorigénicité, réalisés dans les souris Nude, permettent d’établir que l’expression de Tspan8 procure aux cellules de mélanome un pouvoir tumorigène. À long terme, ce travail vise à faire émerger de nouveaux marqueurs de pronostic mais aussi de nouvelles cibles thérapeutiques visant à bloquer la progression du mélanome avant l’apparition des métastases / Cutaneous melanoma is the most aggressive skin cancer since its great ability to form metastasis. Successful treatment depends on its early detection, as the metastatic form is resistant to current therapies. Melanoma cells, developing from the melanocytes of the skin, proliferate first in the epidermis. Subsequently, some tumor cells acquire an invasive phenotype, degrade the dermal-epidermal junction and invade the dermis where they proliferate and deeply colonize the tissue. Melanoma cells can then enter the circulatory system and disseminate to form metastases in the target organs. Degradation of the basement membrane and invasion of the dermis are therefore the early events of melanoma tumor invasion and the first step leading to the formation of metastases. In the team, we are interested in the study of the poorly understood mechanisms of dermal invasion. We have identified a novel molecular mediator of the early cutaneous melanoma invasion : the Tetraspanin 8. The aim of this thesis was therefore to define the role and the mode of action of this protein. We have established the involvement of Tetraspanin 8 in the loss of melanoma cells anchorage to matrix proteins and also in the degradation of dermalepidermal junction components. We have then obteined data that indicate the involvement of ERK/MAPK and PI3K/AKT signaling pathways, in the invasive phenotype, downstream of the Tetraspanin 8. Although much is yet to be learned ragarding the clinical relevace of Tetraspanin 8 function, we postulate that it could be a promising new therapeutic target in anti-invasive therapies for cutaneous melanoma

O transtorno do espectro do autismo (TEA) constitui um grupo heterogêneo e altamente prevalente de doenças do neurodesenvolvimento. Análises genômicas recentes têm revelado um grande número de variantes genéticas potencialmente deletérias nos pacientes com TEA, a maioria rara ou privada. Um enorme desafio atual é determinar quais dentre essas variantes são as que de fato estão envolvidas na etiologia do transtorno nos pacientes, e quantas variantes patogênicas são necessárias para a penetrância completa do TEA em cada paciente. Recentemente, por meio do sequenciamento completo do exoma de um subgrupo de pacientes com TEA não-sindrômico - nos quais observamos hiperfuncionamento da via de sinalização intracelular mTORC1 - identificamos que um dos pacientes (referido como F2688) é heterozigoto composto para variantes de substituição de aminoácidos raras e potencialmente deletérias no gene ELN. Este gene codifica Relina, uma grande glicoproteína de matriz extracelular que, por meio da ativação da proteína Dab1 e de diferentes vias de sinalização intracelular, controla a migração e o posicionamento dos neurônios, a arborização de neuritos, e o funcionamento das sinapses em várias regiões do encéfalo, tanto no desenvolvimento embrionário como na vida adulta. Estudos anteriores já haviam descrito variantes em heterozigose potencialmente de perda de função no gene RELN em pacientes com TEA; contudo, nenhum desses estudos investigou disfunção da sinalização Relina-Dab1 nos pacientes e, portanto, os efeitos moleculares e celulares de tais variantes sobre células neurais humanas ainda são poucos explorados. Neste trabalho, utilizando células neuroprogenitoras (NPCs) derivadas de células-tronco pluripotentes induzidas do paciente F2688, de outros pacientes com TEA sem mutação em RELN (n=5) e de indivíduos controles (n=5), nós descrevemos que as NPCs do paciente F2688 apresentam: i) disfunção da via de sinalização Relina-Dab1; ii) hiperfuncionamento da via de sinalização mTORC1; iii) crosstalk anormal entre as vias de sinalização Relina-Dab1 e mTORC1, o qual é atenuado com o uso da rapamicina, um inibidor específico de mTORC1. Portanto, nossos resultados sugerem, pela primeira vez, uma relação anormal entre as vias de sinalização Relina-Dab1 e mTORC1 em TEA não-sindrômico / Autism Spectrum Disorder (ASD) is a heterogeneous and highly prevalent group of neurodevelopmental disorders. Whole-genome-based approaches have generated catalogues of thousands of rare and potentially deleterious genetic variants in ASD patients. However, the challenge now is to identify genuine disease-causing/risk variants among the multitude of variants discovered in each exome/genome and how many variants are required to cause the disease. Recently, we performed whole-exome sequencing in a subgroup of ASD patients - in whom we found mTORC1 signaling hyperfunction - and identified rare and potentially deleterious compound heterozygous variants in the RELN gene in one patient (called as F2688). The RELN gene encodes Reelin, a large secreted glycoprotein that controls neuronal migration, layer formation, neurite outgrowth, and plasticity of synapses in both the developing and the adult brain. Evidence from previous studies suggests that certain potential loss-of-function variants in RELN gene can contribute to ASD susceptibility; however, few studies today have directly demonstrated impairment of the Reelin signal transduction cascade in ASD patients and therefore, the molecular and cellular effects of these variants in human neuronal cells are still poorly explored. Here, by using induced pluripotent stem cells derived neuronal progenitor cells from F2688 patient, from other ASD patients who do not carry RELN disrupting variants (n=5) and from control individuals (n=5), we have demonstrated that F2688-derived NPCs show: i) impaired Reelin-Dab1 signaling; ii) overactive mTORC1 signaling; iii) and abnormal crosstalk between mTORC1 and Reelin-Dab1 signaling pathways, which it attenuated by rapamycin (a specific mTORC1 inhibitor). Taken together, our results point to an abnormal interplay between mTORC1 and Reelin-Dab1 networks in nonsyndromic ASD

Les tumeurs de vessie suivent deux voies de progression tumorale. La voie des carcinomes in situ (CIS) qui progressent pour envahir la membrane basale puis le muscle, et la voie des tumeurs papillaires de bas grade qui progressent peu mais qui récidivent fréquemment. Environ 65% des tumeurs papillaires de bas grade présentent une mutation du gène FGFR3 et récemment des protéines de fusion FGFR3-TACC3 ont été observées dans les tumeurs de vessie (dans 10% des tumeurs invasives). Le rôle oncogénique du récepteur FGFR3 muté et de FGFR3-TACC3 a été démontré in vivo et in vitro. Cependant, les voies de signalisation du récepteur FGFR3 muté ou de FGFR3-TACC3 sont à l’heure actuelle très peu caractérisées. Dans ce contexte, deux approches ont été mises en place pour caractériser ces voies de signalisation. La première s’appuie sur l’étude de la phosphorylation des protéines p38, AKT et ERK1/2 par le récepteur FGFR3 muté (S249C) ou sauvage dans la lignée cellulaire fibroblastique NIH3T3, et a permis d’identifier les protéines p38 et AKT comme activées par le récepteur FGFR3 muté et nécessaire pour induire la transformation cellulaire. L’étude de l’activation de ces deux voies de signalisation a été réalisée dans des lignées cellulaires dérivées de tumeurs de vessie exprimant le récepteur FGFR3 muté ou FGFR3-TACC3 de manière endogène et a montré que leur activation était dépendante de celle du récepteur FGFR3. De plus nous avons montré que les protéines p38 et AKT sont impliquées dans le maintien d’une boucle de rétro-contrôle positive entre FGFR3 et MYC : l’activation de FGFR3 induit une surexpression de MYC qui en retour promeut l’expression de FGFR3. La seconde approche est basée sur une étude visant à identifier les partenaires protéiques de FGFR3 par spectrométrie de masse après immunoprécipitation de celui-ci qui avait été réalisée précédemment au laboratoire. L’analyse des données a permis l’obtention d’une liste de 60 protéines identifiées comme partenaires protéiques de FGFR3 avec une grande confiance. La construction d’un réseau à partir de cette liste n’a pas été possible (trop peu d’interactions existant entre ces protéines), nous avons donc développé un algorithme (PEPPER) en collaboration avec un étudiant en bio-informatique au laboratoire, Rémy Nicolle, pour proposer un réseau de signalisation de FGFR3.Les deux approches mises en place au cours de cette thèse nous ont permis de mieux caractériser les voies de signalisation du récepteur FGFR3. L’identification d’une boucle de rétrocontrôle entre FGFR3 et MYC a permis de mieux comprendre pourquoi le récepteur FGFR3 possède des propriétés oncogéniques, et de proposer les protéines p38 et AKT comme cibles thérapeutiques potentielles pour traiter les tumeurs de vessie exprimant le récepteur FGFR3 altéré. La construction du réseau de signalisation de FGFR3 via PEPPER donne une vue d’ensemble des voies de signalisation de FGFR3 et ouvre de nouvelles pistes à étudier. / Bladder cancer progression can be divided in two main pathways. The pathway of In Situ Carcinoma (CIS) which progress through an invasion of the basement membrane and then the muscle and the pathway of Ta papillary tumors which change little but recur frequently after tumor resection. Approximately 65% of Ta papillary tumors harboring a FGFR3 mutation and recently FGFR3-TACC3 fusion proteins have been observed in bladder tumors (about 10% of bladder tumors). The oncogenic role of the mutated FGFR3 receptor and of the FGFR3-TACC3 fusion protein has been demonstrated in vivo and in vitro. However signaling pathways activated by the mutated FGFR3 receptor or by the FGFR3-TACC3 fusion protein are currently poorly characterized.In this context, two approaches have been developed to characterize these signaling pathways. The first is based on the study of p38, AKT and ERK1/2 phosphorylation by the mutated receptor (S249C) or the wild type receptor in the NIH3T3 fibroblastic cell line. This study allowed identifying p38 and AKT as activated by the mutated FGFR3 receptor. Moreover, activation of p38 and AKT by the mutated receptor is critical for cell transformation. Study of the activation of these two signaling has been realized in human bladder cancer cell lines endogenously expressing the mutated FGFR3 receptor or the FGFR3-TACC3 fusion protein. Moreover, we showed that p38 and AKT are involved in the maintenance of a FGFR3/MYC feedback positive loop: FGFR3 activation induce MYC over expression which in turns promotes FGFR3 expression. The second approach is based on a study whose aim was to identify FGFR3 proteins partners by mass spectrometry after a FGFR3 immunoprecipitation, which has been previously realized in the lab. Data analyze led to the obtaining of a list of 60 proteins identified has FGFR3 protein partners with a high confidence. Construction of a FGFR3 network with this list was not possible (too little interactions existing between these proteins), so we developed an algorithm (PEPPER) in collaboration with a student in bioinformatics in the lab, Remy Nicolle, to propose a FGFR3 signaling network.The two approaches developed during this thesis allowed us to better characterize the FGFR3 signaling pathways. Identification of a FGFR3/MYC feedback loop allowed us to better understand why the altered FGFR3 has oncogenic properties and to propose p38 and AKT as news promising therapeutic targets, to treat human bladder tumors harboring the altered FGFR3 receptor. Construction of the FGFR3 signaling network with the algorithme PEPPER give an overview of the FGFR3 signaling pathways and open new tracks to explore.

During pregnancy, 4 - 7% of women suffer from major depressive disorder. When antidepressive treatment is needed, selective serotonin reuptake inhibitors (SSRIs) are the most commonly used. Although severe complications from SSRI treatment are rare, association with a number of adverse pregnancy and fetal outcomes has been found. Also, antenatal depression per se has been shown to affect pregnancy outcomes. The overall aim of this thesis was to examine the effects of SSRIs on human placenta and embryo. In the first study, gene expression was investigated in placenta from depressed, SSRI-treated and healthy pregnant women, using microarray analysis. Antenatal depression and SSRI treatment induced alterations in gene expression, but only 20 genes in common were noted. Validation with qRT-PCR showed that six out of seven selected genes were altered in SSRI-treated women compared with controls, and two genes were altered between depressed women and controls. In study two, the protein levels in placenta from depressed, SSRI-treated and healthy pregnant women were investigated, focusing on the NGF signaling pathway. NGF, phosphorylated Raf-1, ROCK2 and phosphorylated ROCK2, were altered in both SSRI-treated and depressed women, although the proteins were regulated differently in the two groups. In the third study, human embryos were treated with fluoxetine. Embryo development and protein expression were studied. Fluoxetine had some effect on the timing of embryo developmental stages. Also, several proteins were uniquely found in fluoxetine-treated embryos compared with untreated embryos. Fluoxetine also altered the levels of proteins secreted from the embryo. In the fourth study, the human neuroblastoma cell line SH-SY5Y/TrkA was treated with TPA and NGF. The activation of Raf-1 was investigated and the involvement of Ras and PKC was studied. Both NGF and TPA activated Raf-1, but to a different extent and via different pathways. The NGF-induced activation of Raf-1 was mediated via Ras, while TPA induced signaling via PKC. In conclusion, SSRI treatment and antenatal depression influence placental gene and protein expression. These findings may affect placental development and function, which in turn could affect fetal development. Also, direct exposure of embryos to fluoxetine has some effects on embryo development and protein expression, which may affect the development of the fetus.

Le striatum dorsal et le noyau accumbens (NAc) jouent un rôle crucial dans la sélection et l’exécution de mouvements résultant de l’intégration de signaux dopaminergiques et d’informations glutamatergiques sensorielles. A ce jour, les mécanismes moléculaires à travers lesquels la dopamine (DA) régule la plasticité des neurones épineux moyens du striatum (MSNs) sont peu connus. La synthèse des protéines est un événement essentiel requis pour la plasticité synaptique et la mémoire à long terme. Dans de nombreuses régions cérébrales, l’initiation, étant l'étape limitante de la synthèse protéique, est contrôlée par la phosphorylation de facteurs d’initiation de la traduction (eIFs). Notre hypothèse est que la DA pourrait réguler la traduction d’ARNm dans le striatum à travers des mécanismes moléculaires similaires. La première partie de cette thèse visait à étudier le rôle de la DA dans la régulation de la machinerie de traduction dans les MSNs. Pour ce faire, nous avons analysé au niveau du striatum, la phosphorylation de différents eIFs en réponse à l’administration aigue ou répétée de d-amphetamine (d-amph), entraînant une augmentation transitoire ou de longue durée de la transmission dopaminergique, respectivement. Bien que l’administration de la d-amph est associée à une légère augmentation de pS209-eIF4E, l’état de phosphorylation de S1108-eIF4G reste inchangé. En revanche, une forte augmentation de p51-eIF2α a été observée après administration répétée d-amph. Nous démontrons que la phosphorylation de 51-eIF2α est corrélée à une diminution transitoire de la synthèse protéique globale dans le striatum. En outre, la d-amph induit également une importante augmentation de la phosphorylation de la protéine ribosomale S6 (rpS6). Cet effet se produit spécifiquement dans MSNs exprimant le récepteur D1 à la DA et implique la cascade de signalisation AMPc/PKA/DARPP-32, tout en étant indépendant des voies mTORC1/S6K et ERK. La phosphorylation de rpS6 est couramment utilisée pour marquer de l'activité neuronale bien que son rôle biologique dans le cerveau reste énigmatique. Compte tenu sa régulation significative par la DA, la deuxième partie de cette thèse a eu pour but d’acquérir de nouvelles connaissances sur la fonction de la phosphorylation de rpS6 en utilisant un modèle de souris rpS6 déficient de ses sites de phosphorylations, rpS6P-/-. Dans ces souris transgéniques la synthèse protéique globale est normale dans diverses régions du cerveau. Néanmoins, les souris rpS6P -/- présentent une altération de la traduction d'un sous-ensemble de ARNm, ceci sélectivement dans le NAc, suggérant le rôle potentiel de la phosphorylation de rpS6 dans la régulation de la traduction de transcrits bien spécifiques au sein de cette sous-région du striatum. Dans l'ensemble, les résultats présentés dans cette thèse permettent une meilleure compréhension des mécanismes engagés par DA pour contrôler la traduction d’ ARNm dans les MSNs du striatum. / The dorsal striatum and the nucleus accumbens (NAc) process dopamine (DA) signals in order to generate appropriate behavior in response to given glutamatergic sensory cues. The molecular mechanisms through which DA promotes long-lasting changes in striatal GABAergic medium-sized spiny neurons (MSNs) are still not fully understood. It is widely accepted that protein synthesis is an essential event required for several forms of synaptic plasticity and long-term memory. In various brain areas, initiation is the rate-limiting step of translation and is regulated through phosphorylation of translation initiation factors (eIFs). Whether DA could regulate mRNA translation in the striatum through similar mechanisms is yet poorly investigated. A first part of this thesis aimed to shed light on the role of DA in the regulation of the translational machinery in MSNs. Here, we measured the phosphorylation state of eIFs following single and repeated in vivo d-amphetamine (d-amph) administration, resulting in a transient or long-lasting increase of the dopaminergic transmission, respectively. Although d-amph exposure slightly enhances the striatal pS209-eIF4E, pS1108-eIF4G remains unchanged. In contrast, a strong increase in p51-eIF2α is observed after repeated d-amph administration. We demonstrate that d-amph-induced p51-eIF2α is associated to a transient decrease in generall striatal protein synthesis. In addition, d-amph markedly increases the striatal phosphorylation of the 40S ribosomal protein S6 (rpS6). This effect occurs selectively in D1 DA receptor (D1R)-expressing MSNs and requires the cAMP/PKA/DARPP-32 cascade but is independent of mTORC1/S6K and ERK signaling. rpS6 phosphorylation is commonly used as a marker for neuronal activity even though its biological role in the brain remains puzzling. Given the significant regulation of striatal rpS6 phosphorylation by DA, the second part of this thesis sought to gain new insights into the function of this post-translational event by using a phosphodeficient rpS6P-/- mouse model. We showed that rpS6P-/- mice display unaltered global protein synthesis in different brain regions. Nonetheless, rpS6P-/- mice exhibit impaired translation of a subset of mRNA selectively in the NAc, pointing to the potential role of rpS6 phosphorylation in the regulation of transcript-specific translation within this striatal sub-region. Overall, the results presented in this thesis provide a better understanding of the mechanisms engaged by DA to control mRNA translation in striatal MSNs.

L'angiogenèse est un processus physiologique qui correspond à la formation de nouveaux vaisseaux sanguins à partir d'un réseau vasculaire préexistant et est régulée par l'équilibre entre les facteurs endogènes pro- et anti-angiogéniques. La rupture de cet équilibre est associée à de nombreuses pathologies dont l'ischémie, la rétinopathie ou encore la progression tumorale. Etant donné que les cellules endothéliales, principal type cellulaire composant les vaisseaux sanguins expriment les récepteurs à activité tyrosine kinase du facteur anticoagulant, la protéine S, Tyro3, Axl et Mer et produisent de la protéine S, l'objectif de ce travail est d'étudier le rôle, de la protéine S dans l'angiogenèse. Dans la première partie de ce travail, nous avons montré in vivo que la protéine S inhibe l'angiogenèse induite par les facteurs pro-angiogéniques (VEGFA et FGF2). Parallèlement, nous avons observé in vitro une inhibition par la protéine S de la prolifération et de la migration des cellules endothéliales induites par le VEGFA. Cet effet est corrélé à l'inhibition par la protéine S des voies de signalisation des MAP-Kinases et de la phosphatidylinositol 3-kinase (PIK3) induites par le VEGFA. Nous avons ensuite mis en évidence, par l'utilisation d'inhibiteurs pharmacologiques et de petits ARNs interférents, que la protéine S inhibe, via l'activation du récepteur Mer et le recrutement de la protéine phosphatase SHP2, l'activation du VEGFR2, le principal récepteur du VEGFA. Dans la deuxième partie, nous avons montré de manière intéressante que le rôle joué par la protéine S lors de l'angiogenèse est plus complexe, puisqu'elle est capable d'activer directement la voie de signalisatio / Angiogenesis is a physiological process that leads to new blood vessel formation and is regulated by a balance between pro-and anti-angiogenic endogenous factors. Disruption of this balance leads to many pathologies such as ischemia, retinopathies or tumor growth. Because endothelial cells, the main cellular type composing blood vessels, produce the anticoagulant factor, protein S and express its tyrosine kinase receptors Tyro3, Axl and Mer, we investigated the implication of protein S in angiogenesis. In the first part of this work, we demonstrated that protein S inhibits pro-angiogenic factors (VEGFA and FGF2)-induced angiogenesis in vivo. We also observed an inhibition of VEGFA-dependent endothelial cell proliferation and migration induced by protein S. These effects were correlated with protein S induced inhibition of VEGFA-dependent MAP-Kinases (Erk1, Erk2) and phosphatidylinositol 3-kinase (PIK3) activation. Furthermore, we demonstrated, using pharmacological inhibitors and small interfering RNAs, that protein S inhibits VEGFA-induced VEGFR-2 activation through Mer receptor activation and SHP2 protein phosphatase recruitment. In the second part, we demonstrated that, protein S on its own, is able to induce MAP-kinases pathway activation and endothelial cells proliferation. These cellular and molecular effects involved Mer receptor and SHP2 protein activation and required protein kinase SRC recruitment. Our results describe for the first time that protein S is an endogenous regulator for angiogenesis both in vitro and in vivo and may form the framework for the use of protein S as part of an anti-angiogenic treatment.

A l’origine de l’hématopoïèse se trouve les cellules souches hématopoïétiques (CSH). Elles constituent un pool de cellules rares présentes dans la moelle osseuse aux niveaux de zones particulières de l’os appelées niche. Les cellules de la niche produisent des cytokines, telles que la thrombopoïétine (TPO), qui régulent les CSH en contrôlant leur quiescence et leur auto-renouvellement. Peu de choses sont connues sur les mécanismes mis en place par la CSH et son environnement pour faire face aux dommages de l’ADN, notamment induits lors de radio- ou chimio-thérapies. Durant cette étude, nous avons mis en évidence un nouveau rôle de la TPO et de son récepteur Mpl dans la réparation de l’ADN des CSH en réponse à des stress génotoxiques. Les CSH déficientes ou haplo-insuffisantes pour Mpl, ou les CSH sauvages et cultivées en absence de TPO, présentent un défaut de réparation et une instabilité génomique. En réponse à l’irradiation, la TPO potentialise l’activation de la voie NF-kB qui permet l’induction du gène précoce Iex-1. La TPO est également l’activateur majeur de la voie ERK dans les CSH. IEX-1 et pERK forment un complexe tripartite avec DNA-PK, une protéine clé de la voie Non Homologous End Joining (NHEJ). La DNA-PK est fortement activée par la TPO, ce qui augmente la fidélité et l’efficacité de la voie NHEJ et permet d’améliorer l’intégrité génomique des CSH. Par ailleurs, nous montrons qu’une simple injection de TPO ou de son agoniste Romiplostim, avant irradiation ou injection de doxorubicine, limite la mutagénèse des CSH et leur perte de fonction associée. Cet effet est spécifique de la TPO, d’autres cytokines comme le SCF et le Flt3-L, n’ont aucun effet sur la réparation. Ces résultats montrent que la TPO contrôle directement les voies de signalisation aboutissant à la réparation de l’ADN des CSH. Ils ouvrent des perspectives nouvelles pour l’utilisation des agonistes de la TPO comme adjuvant protecteur avant radio- ou chimiothérapie pour minimiser les risques de développement de leucémies aigües myéloïdes secondaires. L’expression de Mpl étant haploinsuffisante pour la fonction de réparation de l’ADN, ces résultats suggèrent que Mpl pourrait être tumeur suppresseur en réponse aux traitements chimio-ou radio-thérapeutiques. / Hematopoietic stem cells (HSC) are at the beginning of hematopoeisis. They constitute a pool of rare cells in bone marrow in specifics zones of bones called niche. Niche’s cells produce cytokines, like thrombopoietin (TPO). These cytokines regulates HSC by controlling quiescence and self-renewal. Few are known about mechanism used by HSC and its environment to prevent DNA damage, and especially those induced by radio- or chemo-therapies. In this study, we discover a new role of TPO and its receptor Mpl in DNA repair of HSC in response to genotoxic stress. HSC without Mpl, or wild type HSC cultured without TPO, show an important defect of DNA repair and genomic instability. In response to irradiation, TPO increases activation of NF-KB pathway that increases induction of IEX-1 early gene. TPO is also the major activator of ERK pathway in HSC. IEX-1 and p-ERK can form a tripartite complex with DNA-PK, a key protein of Non homologous end joining pathway (NHEJ). DNA-PK is fully activated by TPO which increase fidelity and efficacy of NHEJ pathway leading to better genomic integrity of HSC. We also show in this study that a simple injection of TPO or Romiplostim before irradiation or Doxorubicin injection, decrease mutagenesis of HSC and their loss of function associated. This effect of TPO is specific of TPO because other cytokines like SCF or Flt3-L have no effect on the DNA repair. These results show that TPO can directly control signaling pathway leading to repair of HSC’s DNA and open new avenues for TPO agonist using. They can be used to protect HSC before radio- or chemo-therapies and to minimize development of secondary acute myeloid leukemia. Expression of Mpl being haplo-insufficient for DNA repair functions, this result suggests that Mpl could be a tumor suppressor in response to radio- or chemo-therapies treatments.